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GENES AND SCHIZOPHRENIA
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Schizophrenia and related disorders have a major genetic
component. Several large-scale studies have uncovered
a number of possible candidate genes, but these have yet
to be consistently replicated and their underlying biological
function remains elusive. One exception is ‘Disrupted in
schizophrenia 1’ (DISC1), a gene locus originally identified
in a large Scottish family, showing a heavy burden of
major mental illnesses associated with a balanced
t(1;11)(q42.1;q14.3) chromosome translocation. Substan-
tial genetic and biological research on DISC1 has been
reported in the intervening 10 years: DISC1 is now recog-
nized as a genetic risk factor for a spectrum of psychiatric
disorders and DISC1 impacts on many aspects of central
nervous system (CNS) function, including neurodevelop-
ment, neurosignaling, and synaptic functioning. Evidence
has emerged from genetic studies showing a relationship be-
tween DISC1 and quantitative traits, including working
memory, cognitive aging, graymatter volume in the prefron-
tal cortex, and abnormalities in hippocampal structures and
function. DISC1 interacts with numerous proteins also in-
volved in neuronal migration, neurite outgrowth, cytoskel-
etal modulation, and signal transduction, some of which
have been reported as independent genetic susceptibility fac-
tors for psychiatric morbidity. Here, we focus on the grow-
ing literature relating genetic variation in the DISC1
pathway to functional and structural studies of the brain
in humans and in the mouse.
Key words: genetics/schizophrenia/mouse models/
neurodevelopment/neuroimaging
Introduction
Schizophrenia, like many other common diseases, is com-
plex and multifactorial, with contributions from multiple
susceptibility genes, epigenetic, stochastic, and environ-
mental factors.1 Family and twin studies have shown
that genetic factors play a major role in the development
of schizophrenia, and a number of candidate risk genes
have associated with schizophrenia2–4 of which
DTNBP1, NRG1, and DISC1 are particularly relevant
to this review. DISC1 has captured much attention,
not only being associated with schizophrenia but also
predisposing individuals to a wide range of major mental
disorders. Through genetics, cell biology, animal model-
ing, and neuroimaging, the DISC1 pathway is emerging
as a pivotal mediator of quantitative and pathological
brain dysfunction.
The Scottish DISC1 Family and Further Independent
Genetic Evidence
DISC1 was first identified in a large Scottish family with
a high loading of major mental illness.5 Specifically, the
t(1; 11)(q42;q14.3) translocation allele of the DISC1 gene
associates with schizophrenia, bipolar affective disorder,
and recurrent major depression6 (log of the odds ratio =
7.1) in this large family. The first independent evidence
for the involvement of theDISC1 locus in psychiatric illness
came from studies in the Finnish population7,8 in which ev-
idence for linkage of schizophrenia and schizoaffective dis-
order to the 1q32.2–q41 region, proximal to the DISC1
gene, was reported. Further population studies of Taiwan,
Scotland, and Britain/Iceland have also shown linkage of
chromosome 1q32–42 to major psychiatric illness.8
DISC1 Genetic Mouse Models
Although it is difficult to model a psychiatric disorder
like schizophrenia in animals (eg, hallucinations and
delusions are likely to be human specific), anatomical, be-
havioral, and cognitive characteristics have been de-
scribed in patients, and it is feasible to study these in
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animal models.9 There has been much debate about the
functional consequence of the t(1;11) on DISC1. It may
be simply the effect of haploinsufficiency (half normal
levels of DISC1 protein) from conception onwards,10
but others have proposed a dominant negative effect
from expressing a hypothetical truncated DISC1 protein.
On this premise, several transgenic mouse models
expressing anN-terminal or C-terminal truncated protein
have been generated.11–13 Reduced cortical thickness and
partial agenesis of the corpus callosum have been ob-
served in transgenic mice expressing truncated DISC1
generated using a bacterial yeast artificial chromosome
vector.13 Enlarged lateral and third ventricles have
been shown by magnetic resonance imaging (MRI), in
2 other types of transgenic mice in which human
DISC1 cDNA transgenes have been expressed postna-
tally in forebrain cells.11,12 These are similar to features
seen in imaging studies of chronic schizophrenic patients14
(see figure 1). Furthermore, Pletnikov et al12 showed that
isolated embryonic cortical neurons from these mice ex-
hibit far less complex dendritic arborization. Both studies
were also able to show that DISC1 manipulation resulted
in behaviors in the transgenic mice of plausible relevance
to human psychiatric illness, including hyperactivity
(thought to be the equivalent of psychomotor agitation
in humans), increased immobility in the forced swim
test (despair), a deficit in prepulse inhibition (PPI),11
working memory deficits (females only), and decreased
sociability (malesonly).12Although these transgenicmod-
els showed different but overlapping phenotypes, they
provide further support for alteredDISC1 expression pre-
disposing to mental illness.
An earlier study15 looked at mice with missense muta-
tions L100P (leucine to proline) or Q31L (glutamine to
leucine) of DISC1. MRI of both strains showed the mu-
tant mice to have reduced brain volumes compared with
wild-types, especially in the cerebellum, cortex, enterohi-
nal cortex, and thalamus, consistent with the macro-
scopic changes previously observed in schizophrenic
patients.14 Furthermore, the L100P mutant mice showed
behaviors, including profound PPI and latent inhibition
(LI) deficits, akin to those seen in some with schizophre-
nia, and these could be reversed by antipsychotic treat-
ment. In contrast, the Q31L mutant mice showed LI
deficits, but only modest PPI deficits and exhibited
a more depressive-like behavior, partially reversed by
the antidepressant bupropion. Thus, as in humans,
DISC1mutations in mice can lead to 2 very different phe-
notypes.15 Despite the fact that none of thesemousemod-
els exactly matches all features characteristically seen in
human patients, their phenotypes are consistent with hu-
man genetic studies, suggesting extensive locus and allelic
genetic heterogeneity.
DISC1 Imaging Genetics in Humans
DISC1 contains 2 common nonsynonymous single nucle-
otide polymorphisms (SNPs)—Ser704Cys (rs821616) and
Leu607Phe (rs6675281). Ser704Cys has been associated
with schizophrenia and with the structure and function
 Phenotypes of DISC1 mutant mouse studies
Summary of results from several studies: Pl etnikov et al, 2008; Hikida et al, 2007;  
Clapcote et al, 2007; Shen et al, 2008 
• Abnormal  
locomotion  
• Increased  
hyperactivity  
• Decreased social  
interaction  
• Decreased  
reward  
responsiveness  
• Reduced short- 
term potentiation  
causing 
abnormal  
working memory  
• Reduced DISC1- 
PDE4B binding  
• Decreased  
PDE4B activity  
• Abnormal latent  
inhibition (LI)  
• Decreased  
Prepulse  
inhibition (PPI)  
• Reduced brain volume especially in cerebellum, cortex, enterohinal cortex,  
and thalamus  
• Enlarged lateral and third ventricles  
• Reduced cortical thining & partial agenesis of corpus callosum  
• Reduced hippocampal synaptic transmission  
• Reduced parvalbumin staining in medial prefrontal cortex (mPFC)  
1 
Clapcote et al, 2007 : 
• DISC1 L100P mutant mice=schizophrenia-like behaviour 
(profound PPI and LI, reversed by antipsychotics)  
• DISC1 Q31L mutant mice=depressive-like behaviour (only 
modest PPI, reversed by antidepressant) 
Fig. 1.DISC1Expression,Cognitive, andBehavioral PhenotypesReported to beAssociatedWithGeneticVariants ofDISC1 inMice. These
are representative of endophenotypes of major psychiatric illness and likely to be due to widespread DISC1 expression.
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of the hippocampus.16 For example, the Ser allele has been
associated with reduced hippocampal gray matter volume
and altered engagement of the hippocampus during cogni-
tive tasks (see figure 2). Furthermore, the Cys704 allele has
been associatedwithmajor depressive disorder, a reduction
in gray matter volume in the cingulate cortex, and with de-
creased fractional anisotropy in prefrontal white matter.
There is robust evidence for prefrontal cortex (PFC)
abnormalities in psychosis. During verbal fluency tasks,
a classic test of prefrontal function, among healthy vol-
unteers, activation of the PFC in Ser704/Ser704 subjects
was greater, especially of the left hemisphere, a finding
that can be interpreted as a manifestation of less efficient
prefrontal function, with more activation needed to
achieve the same behavioral output.17 These findings
are consistent with reports of association between
Ser704, schizophrenia, and impaired declarative memory
in schizophrenic patients.18
A Japanese MRI study recently reported that healthy
carriers of Cys704 showed significantly larger volumes of
the medial superior frontal gyrus and short insular cortex
than the Ser704 homozygotes, whereas schizophrenic
patients who were carriers of Cys704 tended to have
a smaller supramarginal gyrus than the Ser704 homozy-
gotes.18 There was also noted to be a significant correla-
tion between the right medial superior frontal gyrus
volume and daily dose of antipsychotic medication in
schizophrenic patients who were Ser704 homozygotes.18
Another study investigated the relationship between
the DISC1 Leu607Phe polymorphism and prefrontal
gray matter volumes using MRI.19 Among patients
and healthy volunteers, carriers of Phe607 had signifi-
cantly less gray matter in the superior frontal gyrus
and anterior cingulate gyrus compared with Leu/Leu
homozygotes. Patients who were Phe607 carriers also
showed greater severity of positive symptoms suggesting
that this polymorphism is clinically significant in terms of
psychopathology,19 as suggested by others.20
Raznahan et al21 have recently shown that the devel-
opmental rate of cortical thinning (CT) is dependent
on DISC1 genotype. Consistent with other results,19
Phe607 carriers showed attenuated rates of CT compared
with Leu/Leu homozygotes in bilateral superior frontal
and left angular gyri between the ages of 9 and 23 years.
The Ser704 homozygotes in turn showed accelerated CT
compared with Cys704 carriers in the left anterior cingu-
late and temporal cortices.21 Interestingly, the Ser704Cys
SNP affects DISC1-NDEL1 association, which also has
a well-established role in cortical maturation.22 The next
section of this review focuses on DISC1 interacting part-
ners that we have genetic data from mouse models and
from imaging genetic studies.
DISC1 Interacting Partners: Structural and Anatomical
Changes in Genetic Mouse Models and Imaging Genetic
Studies
DISC1 interacts with numerous neuronal proteins, reflect-
ing the diversity of potential roles that it plays in brain
function. These interactors can be broadly classified into
Fig. 2.DISC1 Expression, Cognitive, and Behavioral Phenotypes Reported to be Associated With Genetic Variants ofDISC1 in Humans.
These are representative of endophenotypes of major psychiatric illness and likely to be due to widespread DISC1 expression.
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those involving: cytoskeleton, cell cycle, signal transduc-
tion, intracellular transport/exocytosis, golgi, and neurode-
velopment.8 An important question remains as to which of
these interactors matters most with respect to schizophre-
nia and as potential targets of drug development.
Neuregulin-1 and Epidermal Growth Factor Receptor B4
Neuregulin-1 (NRG1) is a large multiexon gene on chro-
mosome 8p. It produces multiple isoforms grouped into
types I–VI according to their 5# exon, through alternate
promoters and splicing.23 NRG1 has multiple roles in
the central nervous system (CNS) and in processes of pos-
sible relevance to schizophrenia including: myelination,
glial cell development, migration of radial glial cells during
cortical development, neuronal plasticity, development of
GABAergic interneurons, and expression of dopamine
and serotonin receptors and monoamine transporters.23
Proteolytic cleavage of NRG1 releases the N-terminal
portion, including an epidermal growth factor domain
(critical for cell-cell signaling), which interacts with amem-
brane-associated human epidermal growth factor receptor
B4 (Erb4)-type receptor tyrosine kinase. NRG1 and its re-
ceptor Erb4 are associated with schizophrenia,24 and this
interaction results in receptor dimerization, tyrosine phos-
phorylation, and activation of downstream signaling path-
ways.25
Recently, it was shown that NRG1 and DISC1 link di-
rectly into a common pathway mediated by Erb (Erb 3
and Erb4) receptors and P13K/AKT1 signaling.26 This
study demonstrated that NRG1 andNRG2 increased ex-
pression of a DISC1 isoform in vitro and that NRG1
knockout mice show selective reduction of DISC1 during
neurodevelopment.26
Collectively, these findings suggest that NRG1, Erbs,
AKT1, and DISC1 connect in a common pathway that
regulates neurodevelopment, which may also contribute
to schizophrenia susceptibility. Impaired AKT1 signaling
has also been associated with schizophrenia.27 This study,
therefore, brings together 3 prominent schizophrenia
candidate genes (NRG1, AKT1, and DISC1).
The large number of NRG1 signaling mechanisms and
isoforms parallels the many roles it has in the CNS, many
of which could be involved in schizophrenia. A 5# hap-
lotype (HapICE) in the NRG1 gene has been identified
that associates with schizophrenia,28 a finding supported
by a number of subsequent studies. The NRG1 risk–
associated variants are primarily in noncoding intronic
and promoter regions, leading to the suggestion that
the causative variant may be mediated by altering gene
expression rather than protein levels. This hypothesis
has been strengthened by a study, which demonstrated
that genetic variation at SNP8NRG243177 from
HapICE is associated with altered NRG1 expression.29
Mouse studies have also been informative in under-
standing potential roles for NRG1 in schizophrenia.
Complete knockout of NRG1 expression is lethal,
whereas animals with heterozygous disruption of
NRG1 or of Erb4 receptor function have been shown
to have reduced numbers of N-methyl-D-aspartic acid
receptors30 and increased levels of dopamine receptors28
in the PFC, as well as exhibiting behavioral abnormalities
consistent with schizophrenia.
OurgroupinEdinburghwasthe first torelateNRG1 sta-
tus to brain imaging measures.31 Among 79 subjects from
the Edinburgh High Risk Study, none of whom were
receiving treatment at the time of the study, there was
a highly significant association between the risk allele at
SNP8NRG243177 and psychotic symptoms, across the
course of the study. During the Hayling sentence comple-
tion task (known to activate frontal and temporal brain
regions), functional magnetic resonance imaging (fMRI)
revealed decreased activation of right medial PFC in the
subjectswith the risk (T/T) genotypeatSNP8NRG243177
comparedwith those without the risk allele in the contrast
of sentence completion vs rest. We extended this study to
also investigate the National Adult Reading Test, a mea-
sure of premorbid intelligence quotient (IQ), and found
that the T/T group had a significantly decreased IQ com-
pared with the C/T and C/C groups. A similar pattern of
deficits was seen using the Wechsler Adult Intelligence
Scale, a measure of current IQ, although this effect failed
to reach statistical significance.
In a follow on study, subjects with the risk-associated
SNP8NRG243177 T/T genotype showed reduced white
matter density in the anterior limb of the internal capsule
and evidence of reduced structural connectivity in the
same region using DTI, suggesting that NRG1 may in-
crease susceptibility to psychosis by altering connections
between PFC and other brain regions.32 These findings
further implicate white matter disconnectivity in psycho-
sis. Our group also investigated DTI tractography of
NRG1 and white matter integrity and showed that the
2 risk-associated variants of NRG1 (T allele at
SNP8NRG243177 and C allele at SNP8NRG221533)
are associated with reduced white matter integrity in
the anterior thalamic radiation, which connects the dor-
somedial and anterior thalamic nuclei with the PFC.33 If
this connection is indeed disrupted by psychosis-related
NRG1 variants, as shown here, this would provide a pos-
sible explanation of the abnormal prefrontal function
and connectivity often reported in psychosis.
Collectively then, variation at the NRG1 gene has been
shown to associate with the development of psychotic
symptoms and abnormalities in cortical function and cog-
nition. The fact that the association was with psychotic
symptoms, whether or not subjects developed syndromal
schizophrenia, suggested thatNRG1 is a liability factor for
psychotic symptoms rather than schizophrenia per se.
Pericentriolar Material 1
Pericentriolar material 1 (PCM1) is another putative
schizophrenia susceptibility gene.34 It has also been
17
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shown to interact directly withDISC1.35 DISC1 regulates
PCM1 localization to the centrosome,36 an organelle that
serves as the main microtubule organizing centre. Micro-
tubule assembly is in turn PCM1 dependent.37 Recent
data show that the Leu607Phe polymorphism of
DISC1 affects both centrosomal PCM1 localization
and spontaneous neurotransmitter (noradrenaline) re-
lease but interestingly not microtubule dynamics.38 The
assembly of other centrosomal proteins and microtubule
anchorage and organization are dependent on PCM1,36
suggesting that the DISC1 Leu607Phe polymorphism
could impinge on microtubule function in the absence
of changes in microtubule dynamics. The fact that micro-
tubules act as railroads along which molecular motors
transport intracellular cargoes, such as precursors of syn-
aptic vesicles to axon terminals, provides a possible ex-
planation for why the Leu607Phe polymorphism alters
neurotransmitter release via changes in PCM1-related
changes in microtubule stability and organization.
The PCM1 gene has also been associated with orbito-
frontal gray matter volumetric deficits,39 and there are
a number of haplotypes at the PCM1 locus found to as-
sociate with schizophrenia.40 Voxel-based morphometry
of cases from a UK case-control sample showed a signifi-
cant relative reduction in the volume of orbitofrontal gray
matter in comparison with patients with non-PCM1-
associated schizophrenia, who by contrast showed gray
matter volume reduction in the temporal pole, hippocam-
pus, and interior temporal cortex. PCM1 is part of a mul-
ticomponent complex with DISC1 so it will be interesting
to consider other components as putative contributors to
risk and brain pathology.
Serine-threonine protein kinase AKT1
AKT1 (also known as protein kinase B), a serine/threo-
nine kinase with multiple cellular functions including me-
tabolism, cell stress, cell-cycle regulation, and apoptosis,
also regulates actin organization and cell motility via Gir-
din (Girders of actin filaments), which directly binds ac-
tin at the leading edge of migrating cells.41 Girdin has
been shown to be a DISC1 interactor.41 Its expression
in postnatal rodent brain is localized in the dentate gyrus
and pyramidal cell layers CA1 and CA3 of the hippocam-
pus, mirroring DISC1 expression.41
There is evidence implicating the AKT pathway in
schizophrenia. Genetic variants in AKT have been
reported to associate with schizophrenia.9 A transgenic
mouse has been generated with defective neuronal
AKT1 signaling, which exhibits neurochemical and be-
havioral phenotypes relevant to schizophrenia, including
decreases in prefrontal dopamine signaling and deficits in
sensorimotor gating.42 Impaired cortical AKT1 activity
in these mice significantly enhanced norepinephrine
transporter function, blockade of which reversed the cor-
tical hypodopaminergia and behavioral deficits in these
mice, further supporting the potential of AKT1 and nor-
ephinephrine transporter as drug targets.
Decreased AKT1 activity and decreased AKT-
dependent phosphorylation of glycogen synthase kinase-
3 (GSK-3b), a protein that mediates glucose metabolism
and is also thought to regulate synaptic plasticity, have
been reported in postmortem schizophrenic brains.43
Furthermore, AKT1 knockout mice show impaired
PPI of the startle response. Both typical and atypical an-
tipsychotic drugs enhance AKT1 signaling by activating
AKT1 or by increasing phosphorylation of GSK-3b.44
The mechanism of action is through D2 receptor activa-
tion, which results in AKT1 being inactivated by protein
phosphatase 2A (PP2A), in an arrestin-dependent com-
plex, thereby increasing GSK-3b activity. AKT1 is acti-
vated by phosphorylation, whereas GSK-3b is
inactivated if phosphorylated by AKT1. Levels of the
phosphorylated GSK-3 isoform, GSK-3b, have been
shown to be diminished in the frontal cortex of people
with schizophrenia.27 GSK-3b has recently been identi-
fied as a novel DISC1 interactor, bringing the wingless
(wnt) pathway and b-catenin into the arena for DISC
researchers.45 DISC1 and Girdin dimerize and bind
NDEL1, which in turn binds NDE1 and LIS1, other
key proteins in neurodevelopment. DISC1 therefore
forms higher-order multimers, in a process that alters
the binding of NDEL1 and is sensitive to polymorphic
variation at the Ser704Cys position,46 which has been
previously related by fMRI and working memory tasks
to differential hippocampal engagement in normal hu-
man subjects and also to altered brain expression of
DISC1 partners.8 Like AKT1, DISC1 signaling also
inhibits GSK-3b, and interestingly, from a therapeutic
viewpoint, the mood stabilizer lithium chloride also tar-
gets GSK-3b.
Dysbindin/DTNBP1
DTNBP1, located at 6p22.3, has been identified as a pu-
tative schizophrenia susceptibility gene.47 It has also been
shown to interact with DISC1.48 The molecular mecha-
nism of action of DTNBP1 is not completely understood,
but it is widely distributed in the CNS and appears to be
involved in a range of processes including: postsynaptic
density function and presynaptic glutamatergic transmis-
sion, neuron viability via glutamate signaling resulting in
modulation of dopamine and other neurotransmitter ac-
tivity.25 ‘Sandy’ mice, which have a spontaneous muta-
tion in dysbindin, show cytoarchitectural changes in
the hippocampus49 and also exhibit various abnormal
behaviors similar to schizophrenia.50 Genetic variation
in DTNBP1 has been associated with general cognitive
ability,51 while carriers of a putative schizophrenia risk
haplotype have reported to have a significantly greater
decline in IQ compared with noncarriers suggesting
that DTNBP1 influences the severity of intellectual
18
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decline seen in schizophrenia.52 Furthermore, DTNBP1
has also been associated with imaging phenotypes in
schizophrenia,53 carriers of a risk genotype exhibiting re-
duced brain volume and regional CT. It has been suggested
from the results of these imaging phenotypes thatDTNBP1
may be interacting with other schizophrenia-related risk
factors to affect laminar thickness.
Conclusions
There is an abundance of genetic and biological evidence
supporting a role for DISC1 in risk of psychiatric illness
and in neurodevelopment and signaling. Here, we have
focused on evidence from human brain imaging studies
and from genetically engineered mouse models. We
have extended this review to include comparable studies
ofDISC1 interactors to provide an overview of the role of
the DISC1 pathway. Collectively, a picture is emerging of
how DISC1, through a multiplicity of protein-protein
interactions, including with other known risk genes, reg-
ulates 2 core etiological concepts in schizophrenia,
namely neurodevelopment and neurotransmission. Fur-
ther studies in both humans and rodents of defined ge-
netic status for DISC1 and its many partners are likely
to improve our understanding of schizophrenia etiology
at the molecular and systems level, a prerequisite to the
rational diagnosis of patients, the design of new andmore
effective drug therapies, and the ability to predict the
course of illness and treatment responses.
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